Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

PYY3-36 as an anti-obesity drug target.

Boggiano MM, Chandler PC, Oswald KD, Rodgers RJ, Blundell JE, Ishii Y, Beattie AH, Holch P, Allison DB, Schindler M, Arndt K, Rudolf K, Mark M, Schoelch C, Joost HG, Klaus S, Thöne-Reineke C, Benoit SC, Seeley RJ, Beck-Sickinger AG, Koglin N, Raun K, Madsen K, Wulff BS, Stidsen CE, Birringer M, Kreuzer OJ, Deng XY, Whitcomb DC, Halem H, Taylor J, Dong J, Datta R, Culler M, Ortmann S, Castañeda TR, Tschöp M.

Obes Rev. 2005 Nov;6(4):307-22. Review.

PMID:
16246216
2.

Comparison of independent and combined chronic anti-obese effects of NPY Y2 receptor agonist, PYY(3-36), and NPY Y5 receptor antagonist in diet-induced obese mice.

Moriya R, Mashiko S, Ishihara A, Takahashi T, Murai T, Ito J, Mitobe Y, Oda Z, Iwaasa H, Takehiro F, Kanatani A.

Peptides. 2009 Jul;30(7):1318-22. doi: 10.1016/j.peptides.2009.04.006. Epub 2009 Apr 23.

PMID:
19394383
3.

Physiology: does gut hormone PYY3-36 decrease food intake in rodents?

Tschöp M, Castañeda TR, Joost HG, Thöne-Reineke C, Ortmann S, Klaus S, Hagan MM, Chandler PC, Oswald KD, Benoit SC, Seeley RJ, Kinzig KP, Moran TH, Beck-sickinger AG, Koglin N, Rodgers RJ, Blundell JE, Ishii Y, Beattie AH, Holch P, Allison DB, Raun K, Madsen K, Wulff BS, Stidsen CE, Birringer M, Kreuzer OJ, Schindler M, Arndt K, Rudolf K, Mark M, Deng XY, Whitcomb DC, Halem H, Taylor J, Dong J, Datta R, Culler M, Craney S, Flora D, Smiley D, Heiman ML.

Nature. 2004 Jul 8;430(6996):1 p following 165; discussion 2 p following 165. Erratum in: Nature. 2004 Sep 23;431(7007):1038. Withcomb, DC [corrected to Whitcomb, DC].

PMID:
15243972
4.

Novel selective neuropeptide Y2 receptor PEGylated peptide agonists reduce food intake and body weight in mice.

Lumb KJ, DeCarr LB, Milardo LF, Mays MR, Buckholz TM, Fisk SE, Pellegrino CM, Ortiz AA, Mahle CD.

J Med Chem. 2007 May 3;50(9):2264-8. Epub 2007 Apr 11.

PMID:
17425299
5.

A novel long-acting selective neuropeptide Y2 receptor polyethylene glycol-conjugated peptide agonist reduces food intake and body weight and improves glucose metabolism in rodents.

Ortiz AA, Milardo LF, DeCarr LB, Buckholz TM, Mays MR, Claus TH, Livingston JN, Mahle CD, Lumb KJ.

J Pharmacol Exp Ther. 2007 Nov;323(2):692-700. Epub 2007 Aug 1.

6.

Neuropeptide-Y Y2-receptor agonist, PYY3-36 promotes non-rapid eye movement sleep in rat.

Akanmu MA, Ukponmwan OE, Katayama Y, Honda K.

Neurosci Res. 2006 Mar;54(3):165-70. Epub 2005 Dec 27.

PMID:
16378653
7.

Intravenous peptide YY3-36 and Y2 receptor antagonism in the rat: effects on feeding behaviour.

Scott V, Kimura N, Stark JA, Luckman SM.

J Neuroendocrinol. 2005 Jul;17(7):452-7.

PMID:
15946163
8.

PYY(3-36) reduces food intake and body weight and improves insulin sensitivity in rodent models of diet-induced obesity.

Vrang N, Madsen AN, Tang-Christensen M, Hansen G, Larsen PJ.

Am J Physiol Regul Integr Comp Physiol. 2006 Aug;291(2):R367-75. Epub 2006 Apr 13.

9.

Stimulation of NPY Y2 receptors by PYY3-36 reveals divergent cardiovascular effects of endogenous NPY in rats on different dietary regimens.

Nordheim U, Hofbauer KG.

Am J Physiol Regul Integr Comp Physiol. 2004 Jan;286(1):R138-42. Epub 2003 Oct 9.

10.

Intermittent intraperitoneal infusion of peptide YY(3-36) reduces daily food intake and adiposity in obese rats.

Chelikani PK, Haver AC, Reidelberger RD.

Am J Physiol Regul Integr Comp Physiol. 2007 Jul;293(1):R39-46. Epub 2007 Apr 11.

11.

Lower mean weight after 14 days intravenous administration peptide YY3-36 (PYY3-36) in rabbits.

Sileno AP, Brandt GC, Spann BM, Quay SC.

Int J Obes (Lond). 2006 Jan;30(1):68-72.

PMID:
16172618
12.

Peptide YY, appetite and food intake.

le Roux CW, Bloom SR.

Proc Nutr Soc. 2005 May;64(2):213-6. Review.

PMID:
15960866
13.

Modifying the conserved C-terminal tyrosine of the peptide hormone PYY3-36 to improve Y2 receptor selectivity.

Pedersen SL, Holst B, Vrang N, Jensen KJ.

J Pept Sci. 2009 Nov;15(11):753-9. doi: 10.1002/psc.1170.

PMID:
19739125
14.

Peptide YY: a potential therapy for obesity.

Renshaw D, Batterham RL.

Curr Drug Targets. 2005 Mar;6(2):171-9. Review.

PMID:
15777187
15.

Peptide hormone isoforms: N-terminally branched PYY3-36 isoforms give improved lipid and fat-cell metabolism in diet-induced obese mice.

Pedersen SL, Sasikumar PG, Chelur S, Holst B, Artmann A, Jensen KJ, Vrang N.

J Pept Sci. 2010 Nov;16(11):664-73. doi: 10.1002/psc.1281.

PMID:
20853314
16.
17.

PYY transgenic mice are protected against diet-induced and genetic obesity.

Boey D, Lin S, Enriquez RF, Lee NJ, Slack K, Couzens M, Baldock PA, Herzog H, Sainsbury A.

Neuropeptides. 2008 Feb;42(1):19-30. doi: 10.1016/j.npep.2007.11.003. Epub 2007 Dec 27.

PMID:
18164057
18.

Effect of subcutaneous injections of PYY1-36 and PYY3-36 on appetite, ad libitum energy intake, and plasma free fatty acid concentration in obese males.

Sloth B, Davidsen L, Holst JJ, Flint A, Astrup A.

Am J Physiol Endocrinol Metab. 2007 Aug;293(2):E604-9. Epub 2007 Jun 12.

19.

Effects of dipeptidyl peptidase IV on the satiety actions of peptide YY.

Unniappan S, McIntosh CH, Demuth HU, Heiser U, Wolf R, Kieffer TJ.

Diabetologia. 2006 Aug;49(8):1915-23. Epub 2006 Jun 27.

PMID:
16802131
20.

Glyco-scan: varying glycosylation in the sequence of the peptide hormone PYY3-36 and its effect on receptor selectivity.

Pedersen SL, Steentoft C, Vrang N, Jensen KJ.

Chembiochem. 2010 Feb 15;11(3):366-74. doi: 10.1002/cbic.200900661.

PMID:
20049760
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk